Under Pressure: Are Enhanced Global Efforts Enough For Trial Transparency?
Executive Summary
Increasing scrutiny is being placed on trial sponsors and regulators to improve trial data reporting. Researchers complain that, without access to specific data, results cannot be easily duplicated, which inhibits greater understanding of how medicines might work, adversely affecting treatment decisions and health care costs. Are penalties and public reprimands enough to change behavior?
You may also be interested in...
UK Abuzz With Action On Clinical Trial Transparency
In the run-up to a hearing by a UK parliamentary committee on clinical trial transparency, a new report highlights continued non-compliance by some non-commercial sponsors. Concerns have also been raised about the effect of introducing sanctions.
Pharma Told To Get It Right First Time On Clinical Trial Data
Drug companies are complying with their obligation to submit clinical trial results to the US-based ClinicalTrials.gov database, but major errors in their submissions prevent the results from being uploaded in a timely manner.
EMA To Discuss Reactivating Landmark Clinical Trials Transparency Policy
The European Medicines Agency will be looking at reviving its policy on proactive publishing of clinical study reports, which is currently suspended as the agency copes with huge staff losses on account of Brexit.